[go: up one dir, main page]

NO2947086T3 - - Google Patents

Info

Publication number
NO2947086T3
NO2947086T3 NO14836782A NO14836782A NO2947086T3 NO 2947086 T3 NO2947086 T3 NO 2947086T3 NO 14836782 A NO14836782 A NO 14836782A NO 14836782 A NO14836782 A NO 14836782A NO 2947086 T3 NO2947086 T3 NO 2947086T3
Authority
NO
Norway
Application number
NO14836782A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2947086T3 publication Critical patent/NO2947086T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO14836782A 2013-08-12 2014-08-11 NO2947086T3 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013167600 2013-08-12
PCT/JP2014/071158 WO2015022926A1 (ja) 2013-08-12 2014-08-11 新規な縮合ピリミジン化合物又はその塩

Publications (1)

Publication Number Publication Date
NO2947086T3 true NO2947086T3 (ru) 2018-06-02

Family

ID=52468312

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14836782A NO2947086T3 (ru) 2013-08-12 2014-08-11

Country Status (22)

Country Link
US (1) US9580432B2 (ru)
EP (1) EP2947086B1 (ru)
JP (1) JP6035423B2 (ru)
KR (1) KR101828187B1 (ru)
CN (1) CN105452257B (ru)
AU (1) AU2014307437B2 (ru)
BR (1) BR112016002069B1 (ru)
CA (1) CA2921208C (ru)
DK (1) DK2947086T3 (ru)
ES (1) ES2661733T3 (ru)
HU (1) HUE036834T2 (ru)
MX (1) MX360498B (ru)
MY (1) MY171831A (ru)
NO (1) NO2947086T3 (ru)
PH (1) PH12015502737B1 (ru)
PL (1) PL2947086T3 (ru)
PT (1) PT2947086T (ru)
RU (1) RU2666349C2 (ru)
SG (1) SG11201600048VA (ru)
TR (1) TR201802875T4 (ru)
TW (1) TWI585089B (ru)
WO (1) WO2015022926A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170050936A1 (en) 2013-08-23 2017-02-23 Neupharma, Inc. Certain chemical entities, compositions, and methods
TWI638817B (zh) 2015-01-30 2018-10-21 大鵬藥品工業股份有限公司 免疫疾病之預防及/或治療劑
JP6093486B2 (ja) * 2015-01-30 2017-03-08 大鵬薬品工業株式会社 縮合ピリミジン化合物の新規な塩及びその結晶
EP3345907B1 (en) * 2015-09-01 2020-04-22 Taiho Pharmaceutical Co., Ltd. Pyrazolo[3,4-d]pyrimidine compounds or salts thereof
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US9834561B2 (en) * 2015-10-28 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing ibrutinib and its intermediates
HRP20200352T1 (hr) 2016-02-23 2020-06-12 Taiho Pharmaceutical Co., Ltd. Novi kondenzirani pirimidinski spoj ili njegova sol
WO2018035061A1 (en) * 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
MA47696A (fr) * 2017-02-28 2020-01-08 Taiho Pharmaceutical Co Ltd Activateur d'effet antitumoral utilisant un composé pyrazolo[3,4-d]pyrimidine
CA3073375A1 (en) 2017-08-21 2019-02-28 Taiho Pharmaceutical Co., Ltd. Fusion protein of dctn1 protein with ret protein
PT3909584T (pt) * 2019-01-11 2024-01-12 Taiho Pharmaceutical Co Ltd Composto de pirimidina ou um seu sal
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
US20230064254A1 (en) * 2019-12-19 2023-03-02 Taiho Pharmaceutical Co., Ltd. Therapeutic agent containing fused pyrimidine compound as active ingredient
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4183395A4 (en) * 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114736207B (zh) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 一种小分子her2抑制剂的制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2542776A1 (en) 2003-10-27 2005-05-12 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
JP5237108B2 (ja) * 2005-12-08 2013-07-17 アボット・ラボラトリーズ タンパク質キナーゼ阻害薬としての9員ヘテロ二環式化合物
EP2007373A4 (en) 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
EP2089391B1 (en) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EA017865B1 (ru) 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
JP2009235057A (ja) * 2007-10-31 2009-10-15 Santen Pharmaceut Co Ltd 血管新生阻害活性を有する新規インドール誘導体
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2012283775A1 (en) * 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
WO2013010889A1 (en) * 2011-07-15 2013-01-24 Sanofi-Aventis Deutschland Gmbh A drug delivery device
AU2013210403B2 (en) 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
US20160115168A1 (en) 2016-04-28
PH12015502737A1 (en) 2016-03-07
AU2014307437B2 (en) 2016-12-15
MX360498B (es) 2018-11-05
JPWO2015022926A1 (ja) 2017-03-02
WO2015022926A1 (ja) 2015-02-19
TR201802875T4 (tr) 2018-03-21
CN105452257A (zh) 2016-03-30
EP2947086B1 (en) 2018-01-03
SG11201600048VA (en) 2016-03-30
MY171831A (en) 2019-11-01
CN105452257B (zh) 2017-09-05
DK2947086T3 (en) 2018-03-19
EP2947086A1 (en) 2015-11-25
CA2921208C (en) 2018-02-20
KR20160038891A (ko) 2016-04-07
CA2921208A1 (en) 2015-02-19
RU2015156524A (ru) 2017-09-14
EP2947086A4 (en) 2016-06-22
JP6035423B2 (ja) 2016-11-30
BR112016002069B1 (pt) 2020-08-18
TW201536786A (zh) 2015-10-01
AU2014307437A1 (en) 2016-01-21
RU2666349C2 (ru) 2018-09-07
PH12015502737B1 (en) 2018-08-31
US9580432B2 (en) 2017-02-28
BR112016002069A2 (pt) 2017-08-01
PL2947086T3 (pl) 2018-06-29
PT2947086T (pt) 2018-03-09
HK1217703A1 (zh) 2017-01-20
ES2661733T3 (es) 2018-04-03
MX2016001845A (es) 2016-05-16
TWI585089B (zh) 2017-06-01
HUE036834T2 (hu) 2018-08-28
KR101828187B1 (ko) 2018-02-09

Similar Documents

Publication Publication Date Title
AP2016009275A0 (ru)
BR112015007533A2 (ru)
BR102016010778A2 (ru)
BR112014017733A2 (ru)
BR112014017739A2 (ru)
BR112014019326A2 (ru)
BR112014018480A2 (ru)
BR112014020341A2 (ru)
BR112014017855A2 (ru)
BR112014017765A2 (ru)
BR112014017669A2 (ru)
BR112014021878A2 (ru)
NO2947086T3 (ru)
BR112015030897A2 (ru)
BR112014017901A2 (ru)
BR112016001246A2 (ru)
BR112014018207A2 (ru)
BR112015015948A2 (ru)
BR112014017722A2 (ru)
BR112014017653A2 (ru)
BR112014017794A2 (ru)
BR112014017601A2 (ru)
BR112015015312A2 (ru)
BR112014024039A2 (ru)
BR112014018353A2 (ru)